Special Situation
Quitting with Cardiovascular Disease
For people with heart disease or after a heart attack, quitting smoking is one of the most powerful risk-reducing steps available — and the medications used for quitting are generally safe in this group.
Why this group is different
Continuing to smoke after a cardiovascular event carries high risk, so quitting has outsized benefits. Historically there were concerns about nicotine products in heart patients; modern evidence has substantially reassured: NRT, bupropion and varenicline have all been studied in cardiac patients, including trials starting shortly after acute coronary events, without finding elevated cardiovascular event rates.
Recommended approach
- Quit promptly — benefits begin quickly and reduce risk of future events
- Medication is appropriate: varenicline, bupropion and NRT have evidence in cardiac patients
- Combining medication with behavioral support offers the best chance of success
- Coordinate with the treating cardiologist, especially around hospital discharge
- Treat quitting as part of the overall recovery plan alongside diet, exercise and medication adherence
What the evidence says
Randomized trials including post-acute-coronary-syndrome patients found varenicline and bupropion effective and without elevated cardiovascular event rates. Cochrane reviews and subsequent observational analyses support NRT safety in stable cardiovascular disease. National guidelines recommend aggressive cessation support in cardiac patients.
Evidence strength: Strong
Medication notes
Varenicline (e.g., the EVITA trial in acute coronary syndrome patients), bupropion and NRT all have trial evidence in this population. Concerns about cardiovascular side effects from these medications have not been confirmed in trials. Individual risk factors should still be reviewed with a doctor.
Community experience
Community reports from quitters with heart conditions describe the diagnosis or event as the trigger that made quitting stick, often combined with hospital support and family pressure to stop.
Key cautions
- Quit support should be coordinated with the cardiology team, particularly soon after a heart event
- Stopping smoking is safe and does not require tapering down
- Avoid e-cigarettes as a substitute where regulated cessation medications are available and recommended
Sources: Eisenberg et al. (2016), JAMA — EVITA trial of varenicline after acute coronary syndrome; US Surgeon General reports on smoking and cardiovascular disease; NICE NG209 (2021) · Last reviewed: October 2026
Every situation is individual
This page explains the evidence — your clinician can apply it to your case.